{
    "data": [
        {
            "id": "69a1ae3024c37e0001bbfdd2",
            "title": "If You Invested $100 In ProShares Ultra Silver Stock 5 Years Ago, You Would Have This Much Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">ProShares Ultra Silver (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AGQ\" target=\"_blank\">AGQ</a>) has outperformed the market over the past 5 years by 17.99% on an annualized basis producing an average annual return of 30.08%. Currently, ProShares Ultra Silver has a market capitalization of $3.01 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In AGQ:</strong> If an investor had bought $100 of AGQ stock 5 years ago, it would be worth <strong>$378.67</strong> today based on a price of $184.98 for AGQ at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">ProShares Ultra Silver's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50928481/if-you-invested-100-in-proshares-ultra-silver-stock-5-years-ago-you-would-have-this-much-today",
            "pub_date": "2026-02-27 22:46:12",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1ae5f24c37e0001bbfe09",
            "title": "ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>ANI Pharmaceuticals Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"ANIP\" href=\"https://www.benzinga.com/quote/ANIP\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ANIP\" target=\"_blank\">ANIP</a>)<!-- --> shares are down early Friday following the company’s <a href=\"https://www.benzinga.com/pressreleases/26/02/g50922452/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-reaffir\" rel=\"noreferrer noopener\" target=\"_blank\">strong fourth-quarter report</a>.</p><!--/$--><!--$--><p class=\"block core-block\">ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus estimate of $231.53 million</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The Rare Disease segment, which includes products like Cortrophin Gel, saw a remarkable 50.8% growth, contributing $131.3 million to the overall revenue.</p><!--/$--><!--$--><p class=\"block core-block\">In addition, ANI reported a net income of $27.5 million for the fourth quarter, translating to $1.18 per diluted share, a significant turnaround from a net loss of $10.7 million in the prior year.</p><!--/$--><!--$--><p class=\"block core-block\">Adjusted EBITDA for the fourth quarter of 2025 was $65.4 million, an increase of 30.6% from the fourth quarter of 2024.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Expects Over $1 Billion In 2026 Sales</h2><!--/$--><!--$--><p class=\"block core-block\">“2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top-and bottom-line,” said <strong>Nikhil Lalwani,</strong> President and CEO of ANI. </p><!--/$--><!--$--><p class=\"block core-block\">Lalwani expects “significant multi-year growth” for Cortrophin Gel as the company expands into underpenetrated specialty indications and launches a dedicated organization for acute <a href=\"https://www.benzinga.com/general/health-care\" rel=\"noreferrer noopener\" target=\"_blank\">gouty arthritis flares</a>. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">“With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue,” Lalwani added.</p><!--/$--><!--$--><p class=\"block core-block\">For fiscal 2026, ANI expects sales between $1.055-$1.115 billion versus the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $982.54 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The guidance includes Cortrophin Gel sales expectation of $540 million – $575 million, and ILUVIEN sales guidance of $78-$83 million.</p><!--/$--><!--$--><p class=\"block core-block\">ANI Pharmaceuticals sees fiscal 2026 adjusted earnings of $8.83-$9.34 per share compared to the consensus of $8.58, with adjusted EBITDA of $275 million – $290 million.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 5.2% above its 20-day simple moving average (SMA) and 8.1% below its 100-day SMA, indicating some short-term strength but potential resistance in the longer term. Over the past 12 months, shares have increased by 20%, and they are currently positioned closer to their 52-week highs than lows.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, indicating a balanced market sentiment. Meanwhile, MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD indicates mixed momentum, reflecting uncertainty in the stock’s near-term direction.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $99.50</li>\n<li><strong>Key Support</strong>: $54.10</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Buy Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:ANIP/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $95.50. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Guggenheim</strong>: Buy (Raises Target to $124.00) (Jan. 16)</li>\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $100.00) (Dec. 9, 2025)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>ANIP Price Action:</strong> ANI Pharmaceuticals shares were up 3.71% at $80.01 during premarket trading on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928527\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Oakville--On--Canada---August-15--2021-C.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50928527/ani-pharmaceuticals-turns-profit-rare-disease-sales-surge-50",
            "pub_date": "2026-02-27 22:46:59",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1adb224c37e0001bbfd4c",
            "title": "What&#39;s Going On With Rackspace Stock Friday?",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Rackspace Technology, Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"RXT\" href=\"https://www.benzinga.com/quote/RXT\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/RXT\" target=\"_blank\">RXT</a>)<!-- --> shares are down during Friday’s premarket <a href=\"https://www.benzinga.com/pressreleases/26/02/g50884581/rackspace-technology-reports-fourth-quarter-and-full-year-2025-results\" target=\"_blank\">session as the</a> company reported below consensus fiscal 2026 guidance and fourth quarter results on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">The stock’s decline comes during a mixed market day, with major indices showing a downtrend, particularly impacting technology and related sectors.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Earnings Snapshot</h2><!--/$--><!--$--><p class=\"block core-block\">Rackspace Tech reported adjusted EPS loss of one cent per share, which was better than the analyst consensus <a href=\"https://www.benzinga.com/earnings\" target=\"_blank\">estimate of loss of three cents</a>. </p><!--/$--><!--$--><p class=\"block core-block\">The company reported sales of $683 million, which beat the analyst consensus estimate of $672.373 million.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">Revenue declined 0.4% on a reported basis and 1% on a constant currency basis as Private Cloud segment saw revenues decline of 10% on a reported basis and 11% on a constant currency basis.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects fiscal 2026 adjusted EPS of a loss of 20 cents to 15 cents, compared with consensus estimates of 1 cent profit. It forecasts revenue of $2.6 billion to $2.7 billion, versus the <a href=\"https://www.benzinga.com/calendars/guidance\" target=\"_blank\">Street view of $2.719 billion</a>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">RXT Stock: 144% Above 20-Day SMA Despite Death Cross</h2><!--/$--><!--$--><p class=\"block core-block\">Over the past 12 months, Rackspace Technology has seen a decline of 5.39% in its stock value. Currently, the stock is trading significantly above its key moving averages, which typically signals bullish sentiment in the short term. For instance, it stands 144% above the 20-day SMA and 86.7% above the 100-day SMA. However, the presence of a death cross in March, where the 50-day SMA crossed below the 200-day SMA, suggests caution for long-term investors.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">The technical indicators present a mixed view. The RSI is currently at 77.42, indicating that the stock is in the overbought territory, which could precede a pullback. Conversely, the MACD shows a bullish signal, with the MACD line at 24 cents above the signal line, suggesting that upward momentum might continue in the near term.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">RXT Earnings: Analysts Hold with $4.11 Target</h2><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>EPS Estimate: Loss of 4 cents (Up from Loss of 6 cents)</li>\n<li>Revenue Estimate: $672.56 million (Up from $665.40 million)</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions: </strong>The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/RXT/analyst-ratings\" target=\"_blank\">average price target</a> of $4.11. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>RBC Capital</strong>: Sector Perform (Lowers Target to $1.75) (Nov. 10, 2025)</li>\n</ul><!--/$--><!--$--><h2 class=\"wp-block-heading\">RXT Underperforms Tech Sector Peers</h2><!--/$--><!--$--><p class=\"block core-block\">Rackspace Technology has seen its shares decline by 5.39% over the past year, marking a noticeable underperformance when compared to its peers in the tech services field. This deviation highlights potential challenges and areas where Rackspace Technology may need to pivot or improve to regain its competitive edge.</p><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Rackspace Technology’s year-over-year performance significantly lags behind the peer group average, which has seen an increase of 7.92%. This 13.32 percentage point gap underscores the company’s struggles in a sector that, overall, has been experiencing positive growth. This divergence indicates that Rackspace Technology faces unique challenges or is possibly lagging in areas such as innovation, market expansion, or customer acquisition.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>RXT Price Action:</strong> Rackspace Technology shares were down 6.14% at $2.14 during premarket trading on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928348\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Konskie--Poland---July-18--2022-Rackspac.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/26/02/50928348/whats-going-on-with-rackspace-stock-friday",
            "pub_date": "2026-02-27 22:44:06",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1ae1324c37e0001bbfdb5",
            "title": "Ripple CEO Bullish After &#39;Decade Of Work&#39; As Flare CEO Eyes $5B In XRP By Mid-2026",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Ripple</strong> CEO <strong>Brad Garlinghouse</strong> expressed optimism for 2026 as <strong>Flare</strong> CEO <strong>Hugo Philion</strong> targets $5 billion in <strong>XRP</strong> <a class=\"ticker-link\" data-exchange=\"CRYPTO\" data-ticker=\"XRP\" href=\"https://www.benzinga.com/quote/XRP-USD\" rel=\"noopener\" target=\"_blank\">(CRYPTO: </a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/xrp/usd\" target=\"_blank\">XRP</a>)<!-- --> staked on Flare by mid-2026 through direct XRP Ledger integration.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">The ‘Flip The Switch’ Explanation</h3><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Garlinghouse <a href=\"https://x.com/MrVamos194/status/2027181403172163622\" target=\"_blank\">addressed</a> the XRP community’s “flip the switch” narrative at the Sydney conference, explaining there’s no single master trigger event. </p><!--/$--><!--$--><p class=\"block core-block\">“There’s not one switch. There’s a hundred switches. There’s a thousand switches,” he said.</p><!--/$--><!--$--><p class=\"block core-block\">He explained progress comes from hundreds of small steps. </p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">Each development may seem minor individually, but together they create exponential impact. “It’s taken a little longer in some cases. </p><!--/$--><!--$--><p class=\"block core-block\">On the other hand, we’ve made so much progress, and you’re seeing more and more of these little switches flip.”</p><!--/$--><!--$--><p class=\"block core-block\">Garlinghouse expressed optimism for 2026 and beyond. </p><!--/$--><!--$--><p class=\"block core-block\">He credited the community’s role in debunking misinformation and pushing back against doubt as additional switches being flipped. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">“At some point you’re going to feel like, oh my gosh, the switch did get flipped. But it wasn’t one. It was the culmination of a decade of work.”</p><!--/$--><!--$--><p class=\"block core-block\">The phrase originated in January 2019 when Garlinghouse told Fortune that banks were ready to “flip the switch” on xRapid after completing pilot programs. </p><!--/$--><!--$--><p class=\"block core-block\">The community expanded this into a broader belief that one infrastructure or regulatory event would immediately reprice XRP.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"wp-block-heading\">The Flare $5 Billion Target</h3><!--/$--><!--$--><p class=\"block core-block\">Flare CEO Hugo Philion <a href=\"https://x.com/LeaderAlphaNews/status/2027076769539625116\" target=\"_blank\">provided</a> concrete targets during a separate appearance. “I genuinely think we could get to five billion by the middle of 2026 with a good tailwind,” Philion said, referring to XRP value staked on Flare.</p><!--/$--><!--$--><p class=\"block core-block\">Flare is working with Xaman, one of the major XRP Ledger wallets, to create a smart account enabling users to stake directly from XRP Ledger into Flare without touching the bridge or transacting on Flare.</p><!--/$--><!--$--><p class=\"block core-block\">Xaman holds roughly 4 billion XRP through its wallet—approximately $12 billion in value.</p><!--/$--><!--$--><p class=\"block core-block\">Philion believes Flare can capture a reasonable amount of assets used in Xaman through this direct staking integration.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The smart account eliminates friction by letting XRP holders stake through Xaman without learning new interfaces or bridging assets manually. </p><!--/$--><!--$--><p class=\"block core-block\">This direct pathway could unlock billions in dormant XRP for staking on Flare’s network.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928454\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Digital-Art-Xrp-Logo-Symbol--Ripple-Cryp.jpeg",
            "link": "https://www.benzinga.com/crypto/cryptocurrency/26/02/50928454/ripple-ceo-bullish-after-decade-of-work-as-flare-ceo-eyes-5b-in-xrp-by-mid-2026",
            "pub_date": "2026-02-27 22:45:43",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1accf24c37e0001bbfc74",
            "title": "Dow Dips Over 600 Points; US Producer Prices Increase In January",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Friday.</p><!--/$--><!--$--><p class=\"block core-block\">Following the market opening Friday, the Dow traded down 1.25% to 48,879.67 while the NASDAQ dipped 1.20% to 22,604.10. The S&amp;P 500 also fell, dropping, 0.88% to 6,848.16.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Check This Out: <a href=\"https://www.benzinga.com/trading-ideas/dividends/26/01/49901589/how-to-earn-500-a-month-from-goldman-sachs-stock-ahead-of-q4-earnings-2\" target=\"_blank\">How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 Earnings</a></p><!--/$--><!--$--><p class=\"block core-block\"><strong>Leading and Lagging Sectors</strong><br/><br/>Consumer staples shares gained by 0.9% on Friday.</p><!--/$--><!--$--><p class=\"block core-block\">In trading on Friday, information technology stocks fell by 1.8%.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Top Headline</strong></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">U.S. producer prices rose 0.5% month-over-month in January, compared to a revised 0.4% gain in December and above market estimates of 0.3%.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Equities Trading UP<br/>           </strong></p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Equities Trading DOWN</strong></p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Commodities</strong><br/><br/>In commodity news, oil traded up 3.5% to $67.51 while gold traded up 1% at $5,243.90.</p><!--/$--><!--$--><p class=\"block core-block\">Silver traded up 5.8% to $92.640 on Friday, while copper rose 1.4% to $6.0910.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Euro zone</strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">European shares were mostly lower today. The eurozone's STOXX 600 fell 0.1%, while Spain's IBEX 35 Index fell 0.3%. London's FTSE 100 rose 0.5%, Germany's DAX fell 0.2% and France's CAC 40 declined 0.4% during the session.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Asia Pacific Markets</strong></p><!--/$--><!--$--><p class=\"block core-block\">Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.16%, Hong Kong's Hang Seng index surging 0.95%, China's Shanghai Composite rising 0.39% and India's BSE Sensex slipping 1.17%.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Economics</strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">U.S. producer prices rose 0.5% month-over-month in January, compared to a revised 0.4% gain in December and above market estimates of 0.3%.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50928133\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Tallinn--Estonia---August-4th-2023---Scr.jpeg",
            "link": "https://www.benzinga.com/markets/market-summary/26/02/50928133/dow-dips-over-600-points-us-producer-prices-increase-in-january",
            "pub_date": "2026-02-27 22:40:19",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}